Opendata, web and dolomites

G125 SIGNED

A minimally invasive, outpatient treatment for Gastroesophageal Reflux Disease (GERD), resulting in permanent relief from both GERD symptoms and life-long drug dependency

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 G125 project word cloud

Explore the words cloud of the G125 project. It provides you a very rough idea of what is the project "G125" about.

needle    biocompatible    drafted    severe    stimulated    ascentx    normal    symptoms    innovation    20    digestive    acid    microspheres    bore    unfortunately    content    daily    medications    prepare    catheter    inhibitors    ppis    lower    chain    barrier    commercialization    tissue    made    thereby    consists    bulking    gastric    mask    uses    supply    integrity    market    cure    million    syringe    option    reflux    pump    esophagal    plan    ingrowth    clinical    responders    gastroenterological    polymethylmethcrylate    transition    flexible    debilitating    scaffold    least    12    injection    caused    followed    elongated    gastro    enzymes    gastroesophageal    sphincter    invasive    procedure    regurgitation    union    heartburn    patients    disorder    outpatient    esophageal    trial    15    gerd    treat    agent    strategy    injectable    anti    underlying    permanent    proton    medical    treatment    medication    refine    endoscopic    root    sufferers    intervention    diagnosis    g125    pmma    disease    collagen    vascular    area    efs    suspended    cell    people    surgical    les    bovine    fibro    perform   

Project "G125" data sheet

The following table provides information about the project.

Coordinator
ASCENTX MEDICAL EUROPE LIMITED 

Organization address
address: UNIT 6 QUEENS YARD, WHITE POST LANE
city: LONDON
postcode: E95EN
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country United Kingdom [UK]
 Project website http://ascentxmedical.com/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-09-01   to  2019-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ASCENTX MEDICAL EUROPE LIMITED UK (LONDON) coordinator 50˙000.00

Map

 Project objective

Gastroesophageal Reflux Disease (GERD) is a digestive disorder associated with symptoms such as heartburn and regurgitation, and reflux of normal gastric content like gastric acid and digestive enzymes. GERD is caused by a loss of integrity of the gastro-esophageal barrier known as the 'lower esophageal sphincter' (LES). This condition is one of the most common gastroenterological diagnosis in the European Union, with an estimated 15-20 Million daily sufferers. GERD today is typically treated with medications such as proton pump inhibitors (PPIs). Unfortunately, these anti-acid medications only ‘mask’ GERD symptoms, cause severe side-effects long-term, and about 20% of patients are non-responders. Importantly, they do not treat/cure the underlying root cause of acid reflux. For people who have severe GERD and do not respond to medication, invasive surgical intervention remains the only option. G125 is the least invasive outpatient treatment for Gastroesophageal Reflux Disease (GERD). It is a permanent injectable bulking agent for the endoscopic treatment which enables cell growth in the Lower Esophagal Sphincter (LES), thereby providing long term cure for the debilitating symptoms of GERD. G125 uses a tissue-friendly (biocompatible) microspheres made of Polymethylmethcrylate (PMMA) suspended in bovine collagen and an Elongated Flexible Syringe (EFS) which consists of an elongated catheter and a transition bore needle. The PMMA microspheres provide a permanent scaffold for stimulated fibro-vascular tissue ingrowth in the affected area. During the phase 1 project, a go-to-market strategy and a supply chain will be established, as well as further development plan will be drafted. Within the overall innovation project AscentX Medical will refine the endoscopic injection procedure, perform a 12 month clinical trial with 60 patients followed by a scale up of the production to prepare for commercialization.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "G125" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "G125" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

DetectInMen (2019)

Infection detection in human semen

Read More  

PREDICT (2019)

Big Data EEG-Analysis for Advanced Personalised Medicine in Depression

Read More  

ELDICO ED (2019)

ELDICO ED, Shaping the Future of Crystallography - The First Pure Electron Diffraction Equipment for Nano-Crystallography

Read More